Heyholder
‹ Activism Filings

CHOONG ANG VACCINE LABORATORY Q3 profit from the main business KRW 1.6 billion, up 2.9% from a year earlier

CHOONG ANG VACCINE LABORATORY· Periodic Report

AI summary · Not investment advice

Central Vaccine sold KRW 11.5 billion in Q3 and earned KRW 1.6 billion from its main business, up 2.9% from a year earlier and 39.3% from the prior quarter.

Operating profit · 3 months

KRW 1.6 billion

Key facts

Revenue (3 months)
KRW 11.5 billion
Net income (3 months)
KRW -146.4 million
Period
Q3 (cumulative 2026.01.01 ~ 2026.09.30)
Revenue (prior-year 3 months)
KRW 11.0 billion
Revenue (year to date)
KRW 36.0 billion
Operating profit (prior-year 3 months)
KRW 1.5 billion
Operating profit (year to date)
KRW 5.7 billion
Net income (prior-year 3 months)
KRW 1.7 billion
Net income (year to date)
KRW 4.5 billion

Commentary

AI commentary · Not investment advice

What happened

Jungang Vaccine filed its quarterly report for the 3rd quarter of 2026, on a standalone basis. Sales for the latest 3 months were KRW 11.51 billion. That is up 4.8% from a year earlier and down 3.3% from the previous quarter.

In the company's terms

Operating profit (profit from its main business) for the 3 months was KRW 1.59 billion. That is up 2.9% from a year earlier and up 39.3% from the previous quarter.

What changes for shareholders

Net income (final profit after taxes and other costs) for the 3 months was a loss of KRW 146.4 million. A year earlier, the same period had a profit of KRW 1.70 billion. The company swung to a loss compared with both that period and the previous quarter.

For the year to date (January 1 to September 30), sales were KRW 36.00 billion. Operating profit was KRW 5.73 billion. Net income was KRW 4.48 billion.

Comments

No comments yet

Comments from shareholders will appear here.